Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement

Dateline City: 

WHITEHOUSE STATION, N.J. & SEOUL, South Korea

WHITEHOUSE STATION, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck, (NYSE: MRK) known as MSD outside the United States and Canada,
and Samsung Bioepis Co., Ltd., entered into an agreement to develop and
commercialize multiple pre-specified and undisclosed biosimilar
candidates.

Language: 

English

Contact HTML: 

Merck Media Relations:Ronald Rogers, 908-423-6449orMerck Investor Relations:Justin Holko, 908-423-5088orSamsung Bioepis:HongSeok Ji, [phone]

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Corporate News - February 20, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Source Type: news